Eisai Co. And Biogen Present New Clinical Data Demonstrating 3-Years of Continuous Treatment with Dual-Acting LEQEMBI Continues To Significantly Benefit Early Alzheimer's Disease Patients At AAIC 2024
Portfolio Pulse from Benzinga Newsdesk
Eisai Co. and Biogen presented new clinical data at AAIC 2024 showing that 3 years of continuous treatment with LEQEMBI significantly benefits early Alzheimer's disease patients. The data indicates that LEQEMBI improves cognition and function in 51% of patients with no tau/low tau and slows tau spread across all brain regions.
July 30, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen's LEQEMBI shows significant benefits for early Alzheimer's patients, improving cognition and slowing tau spread over 3 years. This positive clinical data could boost investor confidence in Biogen's Alzheimer's treatment pipeline.
The positive clinical data presented at AAIC 2024 demonstrates the efficacy of Biogen's LEQEMBI in treating early Alzheimer's disease, which is likely to boost investor confidence and positively impact Biogen's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100